Huang Yanhong, Dong Wenwu, Li Jing, Zhang Hao, Shan Zhongyan, Teng Weiping
Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital, China Medical University, Liaoning Provincial Key Laboratory of Endocrine Diseases, Shenyang 110001, P, R, China.
BMC Cancer. 2014 May 29;14:383. doi: 10.1186/1471-2407-14-383.
The incidence of papillary thyroid cancer (PTC) is markedly higher in women than men during the reproductive years. In vitro studies have suggested that estrogen may play an important role in the development and progression of PTC through estrogen receptors (ERs). This study aimed to investigate the expression patterns of the two main ER subtypes, α and β1 (wild-type ERβ), in PTC tissue and their clinical significance.
Immunohistochemical staining of thyroid tissue sections was performed to detect ER expression in female patients with PTC (n =89) and nodular thyroid goiter (NTG; n =30) using the Elivision™ plus two-step system. The relationships between ER subtype expression and clinicopathological/biological factors were further analyzed.
The positive percentage and expression levels of ERα were significantly higher in female PTC patients of reproductive age (18-45 years old; n =50) than age-matched female NTG patients (n =30), while ERβ1 exhibited the opposite pattern. There was no difference in ERα or ERβ1 expression between female PTC patients of reproductive age and those of advanced reproductive age (>45 years old; n =39). In the female PTC patients of reproductive age, ERα expression level was positively correlated with that of Ki-67, while ERβ1 was negatively correlated with mutant P53. Furthermore, more patients with exclusively nuclear ERα expression had extrathyroidal extension (ETE) as compared with those with extranuclear ERα localization. VEGF expression was significantly decreased in female PTC patients of reproductive age with only nuclear ERβ1 expression when compared with those with extranuclear ERβ1 localization. In PTC patients of advanced reproductive age, neither ERα nor ERβ1 expression showed any correlation with that of Ki-67, mutant P53, VEGF, tumor size, TNM stage, ETE, or lymph node metastases.
The differential expression patterns of the two ER subtypes between PTC and NTG indicate that ERα may be a useful immunohistochemical marker for differential diagnosis of PTC. The associations of ER subtype expression with Ki-67, mutant P53, VEGF expression and ETE in female PTC patients of reproductive age suggest that estrogen-activated ERα may mediate stimulatory effects on PTC growth and progression whereas ERβ1 has some inhibitory actions.
在生育年龄段,女性甲状腺乳头状癌(PTC)的发病率显著高于男性。体外研究表明,雌激素可能通过雌激素受体(ERs)在PTC的发生和发展中起重要作用。本研究旨在探讨两种主要ER亚型α和β1(野生型ERβ)在PTC组织中的表达模式及其临床意义。
采用Elivision™ plus两步法对89例女性PTC患者和30例结节性甲状腺肿(NTG)患者的甲状腺组织切片进行免疫组织化学染色,检测ER表达。进一步分析ER亚型表达与临床病理/生物学因素之间的关系。
育龄期(18 - 45岁;n = 50)女性PTC患者中ERα的阳性百分比和表达水平显著高于年龄匹配的女性NTG患者(n = 30),而ERβ1则呈现相反的模式。育龄期女性PTC患者与高龄生育期女性(> 45岁;n = 39)的ERα或ERβ1表达无差异。在育龄期女性PTC患者中,ERα表达水平与Ki-67呈正相关,而ERβ1与突变型P53呈负相关。此外,与ERα位于核外的患者相比,ERα仅在核内表达的患者更多出现甲状腺外侵犯(ETE)。与ERβ1位于核外的育龄期女性PTC患者相比,仅核内表达ERβ1的患者VEGF表达显著降低。在高龄生育期PTC患者中,ERα和ERβ1的表达与Ki-67、突变型P53、VEGF、肿瘤大小、TNM分期、ETE或淋巴结转移均无相关性。
PTC和NTG之间两种ER亚型不同的表达模式表明,ERα可能是PTC鉴别诊断的有用免疫组化标志物。育龄期女性PTC患者中ER亚型表达与Ki-67、突变型P53、VEGF表达及ETE的相关性表明,雌激素激活的ERα可能介导对PTC生长和进展的刺激作用,而ERβ1具有一定的抑制作用。